Literature DB >> 22789032

Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology.

Claudia Della Corte1, Danilo Fintini, Ugo Giordano, Marco Cappa, Claudia Brufani, Fabio Majo, Chiara Mennini, Valerio Nobili.   

Abstract

OBJECTIVE: Hepatic steatosis is strongly associated with insulin resistance, but causative mechanisms that link these conditions are still largely unknown. Nowadays, it is difficult to establish whether fatty liver is the cause of insulin resistance or instead the complex metabolic derangements of insulin resistance determine hepatic steatosis and its progression to fibrosis. In patients with familial hypobetalipoproteinemia (FHBL), hepatic steatosis is because of the genetically determined defective form of apolipoprotein B, independently of metabolic derangements. Therefore patients with FHBL represent a good in vivo model to evaluate the relationships between fatty liver and insulin sensitivity.
METHODS: We evaluated insulin resistance through HOMA-IR in 60 children with echografic and histological features of steatosis; 30 of whom had nonalcoholic fatty liver disease (NAFLD) and 30 had FHBL.
RESULTS: All patients had histological features of hepatic steatosis. Patients with FHBL were hypolipidemic, as expected. No significant differences between two groups were observed in liver function tests. IRI and HOMA-IR were statistically higher in NAFLD subjects compared to the FHBL group.
CONCLUSION: In our study, we demonstrated that in children with FHBL, hepatic steatosis is dissociated from insulin resistance. This finding suggests that fat accumulation per se may be not a sufficient causal factor leading to insulin resistance, and that other mediators may be involved in the development of alteration in glucose metabolism and metabolic syndrome in patients with NAFLD.
© 2012 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22789032     DOI: 10.1111/j.1365-2265.2012.04498.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

Review 1.  Hypobetalipoproteinemia and abetalipoproteinemia.

Authors:  Francine K Welty
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

Review 2.  Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.

Authors:  Robert A Hegele; Samuel S Gidding; Henry N Ginsberg; Ruth McPherson; Frederick J Raal; Daniel J Rader; Jennifer G Robinson; Francine K Welty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-16       Impact factor: 8.311

Review 3.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

4.  Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?

Authors:  Marialena Mouzaki; Amy Shah; Ana Catalina Arce-Clachar; Jennifer Hardy; Kristin Bramlage; Stavra A Xanthakos
Journal:  J Clin Lipidol       Date:  2019-02-14       Impact factor: 4.766

5.  Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.

Authors:  Eduardo Vilar-Gomez; Samer Gawrieh; Tiebing Liang; Adam D McIntyre; Robert A Hegele; Naga Chalasani
Journal:  J Clin Lipidol       Date:  2020-12-27       Impact factor: 4.766

6.  Adiponectin deficiency rescues high-fat diet-induced hepatic injury, apoptosis and autophagy loss despite persistent steatosis.

Authors:  R Guo; S Nair; Y Zhang; J Ren
Journal:  Int J Obes (Lond)       Date:  2017-05-31       Impact factor: 5.551

Review 7.  The Role of Hepatic Fat Accumulation in Glucose and Insulin Homeostasis-Dysregulation by the Liver.

Authors:  Amalie London; Anne-Marie Lundsgaard; Bente Kiens; Kirstine Nyvold Bojsen-Møller
Journal:  J Clin Med       Date:  2021-01-20       Impact factor: 4.241

Review 8.  Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?

Authors:  Francesco Baratta; Daniele Pastori; Licia Polimeni; Giulia Tozzi; Francesco Violi; Francesco Angelico; Maria Del Ben
Journal:  Int J Mol Sci       Date:  2015-11-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.